News
EMA recognizes Takeda’s pioglitazone-containing medicines remain a valid treatment option for appropriate type 2 diabetes patients
Takeda Pharmaceutical Company Limited announced that at the request of the European Commission (EC), the European Medicines Agency (EMA)’s Committee for Medical Products for Human Use (CHMP) has clarified the label changes for pioglitazone-containing medicines recommended in July of...
News
BYETTA Approved for Use with Insulin Glargine in the U.S.
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new use for BYETTA® (exenatide) injection. BYETTA is now approved as an add-on therapy to insulin glargine, with...
News
Vertex Submits Application for Priority Review and Approval of KALYDECO
Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KALYDECO™ (VX-770, ivacaftor), a medicine in development that targets the defective protein that causes cystic fibrosis (CF)....
News
Oxford BioMedica Announces US IND Approval for Novel Ocular Product
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat®, a novel gene-based treatment for Usher...
News
Norgine and Jubilant Announce Discovery Collaboration in Gastrointestinal Therapeutic Area
Norgine, a leading European speciality pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated pharma & life sciences company of India, announced today, that they have entered into a discovery partnership....
News
Teva Completes Acquisition of Cephalon
Teva Pharmaceutical Industries Ltd.announced that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for...
News
Agilent Technologies and Oxford Gene Technology Expand Microarray and Sequencing Partnership
Agilent Technologies Inc. and Oxford Gene Technology today announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read